Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.09 +0.7%	$8.46	$3.78 ▼ $14.44	$776.03M	0.68	1.18 million shs	1.61 million shs
CRDF Cardiff Oncology	$3.10 +2.6%	$3.09	$2.01 ▼ $5.64	$206.23M	1.61	1.19 million shs	1.50 million shs
DAWN Day One Biopharmaceuticals	$6.32 -1.4%	$6.84	$6.08 ▼ $16.76	$640.61M	-1.29	1.13 million shs	1.50 million shs
GYRE Gyre Therapeutics	$8.07 -3.1%	$9.15	$6.11 ▼ $19.00	$756.62M	1.8	124,941 shs	148,306 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	0.00%	+13.20%	+18.51%	-6.67%	+134.28%
CRDF Cardiff Oncology	0.00%	-18.64%	+7.64%	-17.33%	+24.00%
DAWN Day One Biopharmaceuticals	0.00%	-5.25%	+0.80%	-23.21%	-52.80%
GYRE Gyre Therapeutics	0.00%	+1.00%	-28.01%	-16.89%	-25.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.2908 of 5 stars	3.7	0.0	4.7	0.6	0.8	0.6
CRDF Cardiff Oncology	1.462 of 5 stars	3.5	0.0	0.0	2.9	0.0	0.6
DAWN Day One Biopharmaceuticals	1.672 of 5 stars	3.6	0.0	0.0	2.3	2.5	0.0
GYRE Gyre Therapeutics	0.488 of 5 stars	0.0	3.0	0.0	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	384.05% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	287.10% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	383.73% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRDF, GYRE, DAWN, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/25/2025	DAWN Day One Biopharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$39.00 ➝ $27.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CRDF Cardiff Oncology	$680K	303.30	N/A	N/A	$1.86 per share	1.67
DAWN Day One Biopharmaceuticals	$131.16M	4.88	N/A	N/A	$4.99 per share	1.27
GYRE Gyre Therapeutics	$105.76M	7.15	$0.20 per share	40.86	$1.05 per share	7.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	403.70	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)

Latest CRDF, GYRE, DAWN, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
CRDF Cardiff Oncology	N/A	6.22	6.22
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
GYRE Gyre Therapeutics	N/A	3.60	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CRDF Cardiff Oncology	16.29%
DAWN Day One Biopharmaceuticals	87.95%
GYRE Gyre Therapeutics	23.99%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
CRDF Cardiff Oncology	7.70%
DAWN Day One Biopharmaceuticals	6.20%
GYRE Gyre Therapeutics	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.98 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data

CRDF, GYRE, DAWN, and AVXL Headlines

Recent News About These Companies

Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%

June 20 at 10:12 AM | finance.yahoo.com

Gyre Therapeutics (NASDAQ:GYRE) Trading Up 4% - Here's What Happened

June 17, 2025 | marketbeat.com

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

June 15, 2025 | marketbeat.com

Phase 1 trial of F230 oral therapy for PAH doses 1st participant

June 13, 2025 | pulmonaryhypertensionnews.com

Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 6% - What's Next?

June 11, 2025 | marketbeat.com

GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China

June 11, 2025 | msn.com

Gyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

June 10, 2025 | finanznachrichten.de

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

June 10, 2025 | globenewswire.com

Gyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Here's Why

June 3, 2025 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 7.9% - What's Next?

June 3, 2025 | marketbeat.com

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials

May 31, 2025 | finance.yahoo.com

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials

May 30, 2025 | msn.com

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 29, 2025 | finance.yahoo.com

Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

May 29, 2025 | marketbeat.com

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 29, 2025 | globenewswire.com

Gyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Should You Buy?

May 29, 2025 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?

May 28, 2025 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next?

May 25, 2025 | marketbeat.com

Gyre Therapeutics launches public stock offering

May 24, 2025 | investing.com

Gyre Therapeutics announces new stock offering

May 24, 2025 | uk.investing.com

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB ...

May 24, 2025 | morningstar.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, GYRE, DAWN, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.09 +0.06 (+0.66%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.09 0.00 (0.00%)

As of 06/20/2025 07:45 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Cardiff Oncology NASDAQ:CRDF

$3.10 +0.08 (+2.65%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.10 0.00 (0.00%)

As of 06/20/2025 07:44 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.32 -0.09 (-1.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.32 0.00 (0.00%)

As of 06/20/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Gyre Therapeutics NASDAQ:GYRE

$8.07 -0.26 (-3.12%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$8.07 +0.00 (+0.06%)

As of 06/20/2025 05:39 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time